The proxy reveals heavy reliance on equity-based compensation and continued cash burn as the company awaits Phase 2 CALMA topline results in Q4 2026. The proposed increase in the annual share reserve from 15% to 20% and the additional 5 million share grant signal further dilution ahead. Monitor the say-on-pay vote outcome for investor sentiment on compensation practices, and watch for the CALMA data readout as the primary catalyst.
Price Chart
Executive Summary
IGC Pharma filed its definitive proxy statement for the 2026 Annual Meeting, seeking shareholder approval for seven proposals including the election of Claudia Grimaldi as a Class A director, amendments to the 2018 Omnibus Incentive Plan (changing the annual share reserve adjustment date to January 1 and increasing the annual share reserve percentage from 15% to 20%), a grant of 5,000,000 compensation shares, an advisory say-on-pay vote, ratification of Manohar Chowdhry & Associates as auditor, and an adjournment proposal. The filing highlights the completion of enrollment in the Phase 2 CALMA trial of IGC-AD1 for Alzheimer's agitation, with topline results expected in Q4 2026, and provides financial results showing a net loss of $4.1 million for the nine-month transition period ended December 31, 2025, with revenue of $0.9 million and an operating loss of $7.7 million.
Key Facts
- Annual Meeting scheduled for December 2, 2026; record date October 19, 2026; 116,142,321 shares outstanding.
- Proposal 1: Elect Claudia Grimaldi as Class A director for a three-year term.
- Proposals 2 & 3: Amend 2018 Omnibus Incentive Plan to change annual share reserve adjustment date from April 1 to January 1 and increase annual share reserve percentage from 15% to 20%.
- Proposal 4: Approve grant of 5,000,000 shares of common stock under the 2018 Omnibus Incentive Plan to current and new officers, directors, employees, advisors, and consultants.
- Proposal 5: Non-binding advisory vote on executive compensation (say-on-pay).
- Proposal 6: Ratify Manohar Chowdhry & Associates as independent auditor for fiscal year ending December 31, 2026.
- Proposal 7: Adjournment proposal to solicit additional proxies if needed.
- CEO Ram Mukunda total compensation for the nine-month transition period ended December 31, 2025: $1,891,000 (salary $305,000, bonus $17,000, stock awards $1,530,000, other $39,000).
- CFO Claudia Grimaldi total compensation for the same period: $706,000 (salary $177,000, stock awards $510,000, other $19,000).
- Non-employee director compensation: Richard Prins $255,000, James Moran $170,000, Terry L. Lierman $170,000 (all in stock awards).
- CALMA Phase 2 trial enrollment 100% complete (168 participants randomized); final dosing expected November 2026; topline results expected Q4 2026.
- Revenue for nine months ended December 31, 2025: $869,000 (vs. $941,000 prior year); net loss: $4,146,000 (vs. $5,924,000 prior year); operating loss: $7,745,000 (vs. $6,034,000 prior year).
- Cash used in operating activities: $4.7 million; raised $5.2 million through common stock sales.
- CEO and CFO converted ~$1.15 million of company obligations into 4,274,853 shares at $0.27 per share in June 2026.
- Bradbury Strategic Fund beneficially owns 15.2% of outstanding shares; CEO Ram Mukunda owns 6.6%.
- Three independent directors: Richard Prins, James Moran, Terry L. Lierman.
- Audit committee composed of Richard Prins (Chair) and James Moran; compensation committee composed of James Moran and Richard Prins.
- Five late Section 16(a) filings reported for stock option grants on August 12, 2025.
- Related party transactions: $146,000 working capital loan from Claudia Grimaldi; stock purchase agreements with CEO and CFO for debt conversion; $200,000 share purchase from Moran Global Strategies (owned by director James Moran).
Financial Impact
Net loss of $4.1 million on revenue of $0.9 million for the nine-month transition period; operating loss of $7.7 million; cash burn of $4.7 million from operations.
Risk Factors
- Significant ongoing operating losses and cash burn; company relies on equity issuances for funding.
- Proposed increase in share reserve and additional 5 million share grant will further dilute existing shareholders.
- CALMA Phase 2 trial results are binary and may fail to show efficacy, wiping out a key pipeline asset.
- CEO and CFO compensation heavily weighted toward stock awards, creating potential misalignment if share price declines.
- Late Section 16(a) filings indicate potential insider trading compliance issues.
- Related party transactions (loans from CFO, debt conversion by CEO/CFO, director share purchase) raise governance concerns.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001185185-26-004896 |
| Document: 0001185185-26-004896-index-headers.html | 0001185185-26-004896 |
| Document: 0001185185-26-004896-index.html | 0001185185-26-004896 |
| Document: 0001185185-26-004896.txt | 0001185185-26-004896 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | DEFA14A | $0.2434 | awaiting T+60 | — | $0.2500 (+2.71%) |
Oct 21, 2026 4d ago | DEF 14A | $0.2500 | awaiting T+60 | — | $0.2500 (0.00%) |
Jul 6, 2026 15w ago | 8-K | $0.2780 $0.2689 | ▼ −3.27% | ▼ −5.27% | $0.2500 (−10.07%) |
Jun 8, 2026 19w ago | 8-K | $0.2850 $0.2985 | ▲ +4.74% | ▼ −0.16% | $0.2500 (−12.28%) |
Apr 20, 2026 26w ago | 8-K | $0.3200 $0.2563 | ▲ +19.91% | ▲ +26.81% | $0.2500 (+21.88%) |
Mar 12, 2026 32w ago | 8-K | $0.2800 $0.2900 | ▼ −3.57% | ▲ +7.13% | $0.2500 (+10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers